A Marine λ-Oligocarrageenan Inhibits Migratory and Invasive Ability of MDA-MB-231 Human Breast Cancer Cells through Actions on Heparanase Metabolism and MMP-14/MMP-2 Axis.
Animals
Antineoplastic Agents
/ chemistry
Aquatic Organisms
Breast Neoplasms
Carrageenan
/ chemistry
Cell Line, Tumor
/ drug effects
Cell Movement
/ drug effects
Female
Glucuronidase
/ metabolism
Humans
Inhibitory Concentration 50
Matrix Metalloproteinase 14
/ metabolism
Matrix Metalloproteinase 2
/ metabolism
Rhodophyta
MDA-MB-231
MMP-14
breast cancer
heparanase
heparin
metalloproteinase
oligosaccharide
polysaccharide
shRNA
λ-carrageenan
Journal
Marine drugs
ISSN: 1660-3397
Titre abrégé: Mar Drugs
Pays: Switzerland
ID NLM: 101213729
Informations de publication
Date de publication:
28 Sep 2021
28 Sep 2021
Historique:
received:
21
07
2021
revised:
11
09
2021
accepted:
13
09
2021
entrez:
22
10
2021
pubmed:
23
10
2021
medline:
5
2
2022
Statut:
epublish
Résumé
Sugar-based molecules such as heparins or natural heparan sulfate polysaccharides have been developed and widely studied for controlling heparanase (HPSE) enzymatic activity, a key player in extracellular matrix remodelling during cancer pathogenesis. However, non-enzymatic functions of HPSE have also been described in tumour mechanisms. Given their versatile properties, we hypothesized that sugar-based inhibitors may interfere with enzymatic but also non-enzymatic HPSE activities. In this work, we assessed the effects of an original marine λ-carrageenan derived oligosaccharide (λ-CO) we previously described, along with those of its native counterpart and heparins, on cell viability, proliferation, migration, and invasion of MDA-MB-231 breast cancer cells but also of sh-MDA-MB-231 cells, in which the expression of HPSE was selectively downregulated. We observed no cytotoxic and no anti-proliferative effects of our compounds but surprisingly λ-CO was the most efficient to reduce cell migration and invasion compared with heparins, and in a HPSE-dependent manner. We provided evidence that λ-CO tightly controlled a HPSE/MMP-14/MMP-2 axis, leading to reduced MMP-2 activity. Altogether, this study highlights λ-CO as a potent HPSE "modulator" capable of reducing not only the enzymatic activity of HPSE but also the functions controlled by the HPSE levels.
Identifiants
pubmed: 34677445
pii: md19100546
doi: 10.3390/md19100546
pmc: PMC8539239
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Carrageenan
9000-07-1
heparanase
EC 3.2.1.-
Glucuronidase
EC 3.2.1.31
MMP2 protein, human
EC 3.4.24.24
Matrix Metalloproteinase 2
EC 3.4.24.24
MMP14 protein, human
EC 3.4.24.80
Matrix Metalloproteinase 14
EC 3.4.24.80
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Int J Mol Med. 2013 May;31(5):1234-42
pubmed: 23467544
Clin Cancer Res. 2011 Mar 15;17(6):1382-93
pubmed: 21257720
PLoS One. 2009;4(4):e5181
pubmed: 19360105
iScience. 2019 May 31;15:360-390
pubmed: 31103854
Oncol Rep. 2020 Aug;44(2):711-721
pubmed: 32627022
Anticancer Res. 2019 Oct;39(10):5261-5284
pubmed: 31570422
Int J Breast Cancer. 2014;2014:839094
pubmed: 24800085
Cell Adh Migr. 2020 Dec;14(1):118-128
pubmed: 32538273
Front Biosci (Landmark Ed). 2015 Jun 01;20:1144-63
pubmed: 25961550
Prog Brain Res. 2014;214:313-51
pubmed: 25410364
Cancer Res. 2019 Sep 15;79(18):4557-4566
pubmed: 31350295
Nat Cell Biol. 2000 Oct;2(10):737-44
pubmed: 11025665
Trends Cancer. 2017 Jun;3(6):391-406
pubmed: 28670628
Exp Cell Res. 2008 Aug 1;314(13):2501-14
pubmed: 18602101
Carbohydr Polym. 2016 Jan 1;135:316-23
pubmed: 26453883
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Mar Drugs. 2019 Feb 27;17(3):
pubmed: 30818840
FEBS J. 2013 May;280(10):2294-306
pubmed: 23374281
Nat Med. 1999 Jul;5(7):793-802
pubmed: 10395325
FEBS J. 2017 Jan;284(1):42-55
pubmed: 27758044
Oncotarget. 2014 May 15;5(9):2529-41
pubmed: 24796733
BMC Complement Altern Med. 2016 Aug 04;16:270
pubmed: 27487950
Br J Cancer. 2007 Sep 17;97(6):761-8
pubmed: 17726466
Eur J Cancer. 2010 May;46(7):1177-80
pubmed: 20307970
Biomolecules. 2020 Dec 30;11(1):
pubmed: 33396696
Int J Cancer. 1987 Oct 15;40(4):511-8
pubmed: 3666989
Rambam Maimonides Med J. 2011 Jan 31;2(1):e0019
pubmed: 23908791
Mar Drugs. 2017 May 09;15(5):
pubmed: 28486399
Sci Rep. 2015 Jun 22;5:11062
pubmed: 26098663
Cancer Res. 2015 Sep 15;75(18):3946-57
pubmed: 26249176
Int J Mol Sci. 2019 Feb 15;20(4):
pubmed: 30781344
FASEB J. 2019 Feb;33(2):2910-2927
pubmed: 30332299
J Biol Chem. 2008 Jun 27;283(26):18167-76
pubmed: 18450756
Matrix Biol. 2021 Jun;100-101:173-181
pubmed: 33548399
Molecules. 2018 Nov 08;23(11):
pubmed: 30413079
J Cell Biochem. 2009 Feb 1;106(2):200-9
pubmed: 19115257
J Biol Chem. 2008 Nov 21;283(47):32628-36
pubmed: 18812315
World J Gastroenterol. 2009 Nov 21;15(43):5442-8
pubmed: 19916174
J Gastrointest Surg. 2008 Oct;12(10):1674-81; discussion 1681-2
pubmed: 18704599
Compr Rev Food Sci Food Saf. 2016 Mar;15(2):237-250
pubmed: 33371599
Carbohydr Polym. 2018 Oct 15;198:385-400
pubmed: 30093014
Exp Ther Med. 2014 Oct;8(4):1213-1218
pubmed: 25187827
Oncol Rep. 2017 Jan;37(1):179-184
pubmed: 27878294
Adv Exp Med Biol. 2020;1221:493-522
pubmed: 32274724
Sci Rep. 2019 Apr 30;9(1):6654
pubmed: 31040376
J Biol Chem. 2004 Feb 27;279(9):8047-55
pubmed: 14630925
N Engl J Med. 2020 Feb 27;382(9):810-821
pubmed: 32101663
Invasion Metastasis. 1992;12(2):112-27
pubmed: 1399400
Clin Breast Cancer. 2021 Oct;21(5):383-390
pubmed: 33781662
Carbohydr Polym. 2017 Jun 15;166:156-165
pubmed: 28385219
J Biol Chem. 2004 Oct 15;279(42):44084-92
pubmed: 15292202